The FDA's declaration ends a two-year shortage of tirzepatide, allowing greater access to brand-name medications Zepbound and Mounjaro but causing disruption for compounded alternatives.
With the end of the tirzepatide shortage, compounded weight-loss drugs will no longer be viable alternatives, significantly impacting patients who have relied on them over the past years.
Scott Brunner stated, 'It's those folks that are going to have to scramble,' highlighting the challenges faced by patients who depended on compounded versions during the shortage.
The dramatic interest in compounded medications has been driven by telehealth companies like Ro and Hims, providing these alternatives at lower costs than brand-name drugs.
Collection
[
|
...
]